Cancer News and Research

Latest Cancer News and Research

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

Spectrum Pharmaceuticals, Inc. today announced that it has adjourned its Annual Meeting of Stockholders to 10:30a.m. Pacific Time, Thursday, July 1, 2010, which will be held at the Company's corporate office located at 157 Technology Drive, Irvine, California, 92618.

19 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

OSI Pharmaceuticals, Inc. announced today that its 2% Convertible Senior Subordinated Notes due 2025 are convertible at the option of the holders and will remain convertible at least through July 19, 2010, as provided for in the Indenture governing the notes.

19 Jun 2010

HHS Secretary announces new $250M investment to improve health and well-being of Americans

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced $250 million in new Affordable Care Act investments to support prevention activities and develop the nation's public health infrastructure.

19 Jun 2010

Date set for Ryan Phua Memorial Kids' Ride, Burlingame Criterium

The 7th annual Ryan Phua Memorial Kids' Ride, featuring more than 700 kids of all ages, will once again provide one of the key highlights at the 24th annual Burlingame Criterium, set for Sunday, June 27, 2010. The race activities will fill the streets, restaurants and shops of downtown Burlingame with thousands of competitive cyclists, children, volunteers and spectators. Adding to the excitement of Ryan's Ride, the day's multiple races will culminate in a Men's pro event and a separate Women's pro event.

19 Jun 2010

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

Oncolytics Biotech Inc. today announced that it has been granted its 35th U.S. Patent, # 7,731,951 entitled "Viruses for the Treatment of Cellular Proliferative Disorders." The patent claims cover methods for treating cell proliferative disorders by administering modified vaccinia virus to proliferating cells having an activated Ras-pathway.

19 Jun 2010

BioTime announces warrant discount offer

BioTime, Inc. announced today that it is commencing a warrant discount offer under which it will permit holders of its common share purchase warrants expiring October 31, 2010 to exercise their warrants at a discounted price of $1.818 per share, which represents a discount of $0.182 from the regular warrant exercise price of $2.00 per share.

19 Jun 2010

AdnaGen signs option agreement to license specific antibodies to KellBenx

AdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech company developing proprietary, leading-edge early detection and drug technologies to enable safe, targeted personal cancer treatments, today announced that it has entered into an option agreement to license specific antibodies to KellBenx Inc., a New York-based private biotech firm.

19 Jun 2010

Conscious sedation for glioma resection shortens hospital stay

The recovery time and cost of brain-tumor surgery might both be reduced if surgery is performed while patients are awake during part of the procedure, according to a new study conducted at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

19 Jun 2010

Investigators discover new way to harness thrombin's anti-blood clotting properties

In research led by a Saint Louis University investigator, molecular biologists have discovered a way to harness the enzyme thrombin's anti-blood clotting properties. The finding opens the door to new medications that will treat diseases related to thrombosis, the presence of blood clots in blood vessels, which is responsible for nearly a third of all deaths in the U.S.

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

Akela Pharma first-quarter net loss reduces to $0.4 million

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three months ended March 31, 2010.

19 Jun 2010

LUHS opens clinic to treat debilitating effects of CPP in women

Loyola University Health System has opened a clinic to treat the debilitating effects of chronic pelvic pain in women. The clinic is located at the Loyola Outpatient Center at 2160 S. First Ave., in Maywood.

19 Jun 2010

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

The Republic of Equatorial Guinea (Republica de Guinea Ecuatorial, along with the United Nations Population Fund (UNFPA), is working to strengthen and equip health facilities throughout the country to boost access to reproductive health services. The rebuilding process includes the construction and renovation of health centers and maternity units as well as proper training for medical students.

19 Jun 2010

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.

18 Jun 2010

National Cheng Kung University Hospital's Outpatient Building inaugurated

The Outpatient Building of National Cheng Kung University Hospital was officially inaugurated on June 12th to provide excellent medical service and to further ensure the health of people in Southern Taiwan.

18 Jun 2010

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

18 Jun 2010

Genzyme signs repurchase agreement with Goldman, Sachs

Genzyme Corporation announced today that it has entered into an agreement with Goldman, Sachs & Co. to repurchase $1 billion of Genzyme common stock under an accelerated stock repurchase program. Proceeds from its recently concluded debt offering will be used to support this first tranche of Genzyme's overall $2 billion share repurchase plan announced in May.

18 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

Cancer News and Research

Latest Cancer News and Research

Spectrum Pharmaceuticals adjourns Annual Meeting of Shareholders to July 1, 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

OSI Pharmaceuticals' 2% Senior Subordinated Notes due 2025 to remain convertible through July 19, 2010

HHS Secretary announces new $250M investment to improve health and well-being of Americans

Date set for Ryan Phua Memorial Kids' Ride, Burlingame Criterium

Oncolytics Biotech issued patent that covers methods for treating cell proliferative disorders

BioTime announces warrant discount offer

AdnaGen signs option agreement to license specific antibodies to KellBenx

Conscious sedation for glioma resection shortens hospital stay

Investigators discover new way to harness thrombin's anti-blood clotting properties

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

SAHM strongly recommends HPV vaccines for males

Akela Pharma first-quarter net loss reduces to $0.4 million

LUHS opens clinic to treat debilitating effects of CPP in women

Equatorial Guinea strengthens health facilities to boost access to reproductive health services

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

National Cheng Kung University Hospital's Outpatient Building inaugurated

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Genzyme signs repurchase agreement with Goldman, Sachs

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in